Induction of apoptosis and inhibition of angiogenesis by COX-2 inhibitors in hepatocellular carcinomas
Induction of apoptosis and inhibition of angiogenesis by COX-2 inhibitors in hepatocellular carcinomas
批准号:
11670551
负责人:
KOGA Hironori
金额:
$1.41万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1999
资助国家:
日本
项目状态:
已结题
起止时间:
1999 至 2000
中文摘要
点击翻译按钮获取中文摘要
英文摘要
In this project, we have investigated anti-tumor effect of NS-398, a selective COX-2 inhibitor, on human hepatoma cells, focusing on the agent's ability to induce apoptosis in those cells and the ability to inhibit VEGF production from those cells. Constitutive expression of COX-2 was found by RT-PCR and immunocytochemistry in the hepatoma cells examined. A significant growth-inhibitory effect was demonstrated in NS-398-treated hepatoma cells, however, the effect was not attributable to an increase in apoptotic cells nor to inactivation of COX-2 by NS-398, suggesting involvement of a COX-2-independent mechanism in growth inhibition of hepatoma cells treated with COX-2 inhibitors. While the study was going on, NS-398 has been reported to be not only a COX-2 inhibitor but also a PPAR γ ligand (J Biol Chem, 1999). This finding encouraged us to perform subsequent studies to elucidate the involvement of PPAR γ in growth inhibition in hepatoma cells. PPAR γ was constitutively expressed in all the cell lines (HLF, HuH-7, HAK- 1A, HAK-1B, and HAK-5) and the HCC tissues used in this study. A cytostatic effect of PPAR γ ligands was found in those cell lines, and this inhibition of cell growth was dosage-dependent. G1 arrest was apparently demonstrated in flow cytometric analysis in HLF, HAK-1A, HAK-1B, and HAK-5, all of which showed an increased expression of p21.However, HuH-7, lacking p21 protein expression, did not demonstrate clear arrest in the cell cycle analysis. HLF, which was pRb-deficient, responded most profoundly to a PPAR γ ligand, showing an increased expression in not only p21 but also in p27 and p18. These findings suggested that p21, p27, and p18 might be involved in PPAR γ ligand-induced cell cycle arrest.
期刊论文(30)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
古賀浩徳: "PPARγを介した肝癌細胞の増殖抑制にはp21^<WAF1/CIP1>およびp27^<KIP1>が関与する"Japanese Journal of Cancer Research. 88 (2000)
Hironori Koga:“p21^<WAF1/CIP1>和p27^<KIP1>参与PPARγ介导的肝癌细胞增殖抑制”日本癌症研究杂志88(2000)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Hironori Koga: "Expression of cyclooxygenase-2 in human hepatocellular carcinoma : relevance to tumor de-differentiation"Research Report ′98. 29 (1999)
Hironori Koga:“人类肝细胞癌中环氧合酶 2 的表达:与肿瘤去分化的相关性”研究报告 98(1999)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
古賀浩徳: "胆管障害の機序"肝胆膵. 39. 21-27 (1999)
Hironori Koga:“胆管疾病的机制”《肝胆胰》39. 21-27 (1999)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Hironori Koga, et al.: "Expression of COX-2 in human hepatocellular carcinoma"Hematlogy & Oncology. 38. 116-121 (1999)
Hironori Koga 等人:“COX-2 在人肝细胞癌中的表达”血液学
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
古賀浩徳: "PPAR γを介した肝癌細胞の増殖抑制にはp21WAF1/Cip1およびp27Kip1が関与する"Japanese Journal of Cancer Research. 91(Supple)(in press). (2000)
Hironori Koga:“p21WAF1/Cip1 和 p27Kip1 参与 PPAR γ 介导的肝癌细胞增殖抑制”,日本癌症研究杂志 91(增刊)(印刷中)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 26 条
Biocontrol of parasitic nematodes by using endophyte infected plants as companion planting for horticultural crops
-
批准号:26660016
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.41万
-
财政年份:2014
-
负责人:KOGA Hironori
-
依托单位:
Human T-Cell factor-4 isoform promotes tumorigenicity in a hypoxia-dependent manner
-
批准号:23590999
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.41万
-
财政年份:2011
-
负责人:KOGA Hironori
-
依托单位:
The protective effect of hydrogen on myocardial ischemia-reperfusion injury
-
批准号:20791082
-
项目类别:Grant-in-Aid for Young Scientists (B)
-
资助金额:$2.58万
-
财政年份:2008
-
负责人:KOGA Hironori
-
依托单位:
Chemotherapeutic Effect of Cell-cycle Modulation in Skp2-targeting Strategy for Liver Cancer
-
批准号:16590652
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.24万
-
财政年份:2004
-
负责人:KOGA Hironori
-
依托单位:
国内基金
海外基金
登录
查看更多内容
RGD-68Ga@AuNCs PET监测PRMT5通过VEGFA调节肺腺癌血管新生的功能及机制
-
批准号:82372007
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:谢文晖
-
依托单位:
PROCR信号通路介导的血管新生在卵巢组织移植中的作用及机制研究
-
批准号:82371726
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2023
-
负责人:李文
-
依托单位:
RNA编辑型IGFBP7在肿瘤细胞与肿瘤血管微环境中的调控作用及机制研究
-
批准号:32070790
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2020
-
负责人:徐小燕
-
依托单位:
ROBO4对视网膜血管生成(angiogenesis)的调控及其分子机制
-
批准号:81200692
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2012
-
负责人:陈凌
-
依托单位:
基于新生血管显像研究MSC治疗缺血性脑血管病的转化医学关键问题
-
批准号:81171370
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:朱朝晖
-
依托单位:
探索VASH2转录激活对肝细胞癌血管生成和上皮间质转化的作用及机制
-
批准号:81172267
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:高文涛
-
依托单位:
解析miR-566调控VHL/β-catenin信号通路影响人脑胶质瘤血管新生的分子机制
-
批准号:81101916
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:周旋
-
依托单位:
脂肪组织来源干细胞促进颗粒脂肪游离移植后再血管化机制的实验研究
-
批准号:81171834
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:鲁峰
-
依托单位:
99mTc-3PRGD2 SPECT显像用于评价肺癌抗新生血管药物疗效的动物研究及肺癌诊断临床研究
-
批准号:81171369
-
项目类别:面上项目
-
资助金额:56.0万元
-
批准年份:2011
-
负责人:李方
-
依托单位:
核素靶向示踪肿瘤新生血管作用位点研究
-
批准号:81071183
-
项目类别:面上项目
-
资助金额:32.0万元
-
批准年份:2010
-
负责人:王荣福
-
依托单位: